Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## **144: Filer Information**

Filer CIK0001073387Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationIs the second second

Name Phone E-Mail Address

### **144: Issuer Information**

Name of IssuerIONIS PHARMACEUTICALS INCSEC File Number000-19125Address of Issuer2855 GAZELLE COURT<br/>CARLSBAD<br/>CALIFORNIA<br/>92010Phone7609319200Name of Person for Whose Account the Securities are To Be SoldBENNETT C FRANK

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Officer

Relationship to Issuer

**144: Securities Information** 

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
COMMON STOCK	INSIGHT SECURITIES, INC. 600 CENTRAL STE 293 HIGHLAND PARK IL 60035	22612	1121196.00	143100000	12/14/2023	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

# 144: Securities To Be Sold

Title of Date you Nature of Name of Person from Is Date Amount Date of Nature of

the Class	Acquired	Acquisition Transaction	Whom Acquired		Donor Acquired	of Securities	Payment	Payment *
				Gift?	•	Acquired		
COMMON STOCK	01/13/2022	COMPENSATION	IONIS PHARMACEUTICALS INC.	, 🗖		22612	01/13/2022 CC	OMPENSATION

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	<b>Gross Proceeds</b>
FRANK C. BENNETT 2855 GAZELLE COURT CARLSBAD CA 92010	COMMON STOCK	09/28/2023	4460	207390.00

## 144: Remarks and Signature

Remarks	INSIGHT SECURITIES SOLD 22,612 SHARES OF IONIS PHARMACEUTICALS, INC. FOR FRANK C. BENNETT
Date of Notice	12/15/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/29/2023
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature MICHAEL MAKULA

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)